Want to see GEHC full AI Analyst Report?
GEHC Stock Chart & Stats
$60.58
-$1.38(-2.22%)
At close: 4:00 PM EDT
$60.58
-$1.38(-2.22%)
Day’s Range― - ―
52-Week Range$58.75 - $89.77
Previous CloseN/A
Volume9.13M
Average Volume (3M)4.95M
Market Cap
$29.16B
Enterprise Value$37.74K
Total Cash (Recent Filing)$2.10B
Total Debt (Recent Filing)$10.09B
Price to Earnings (P/E)19.4
Beta1.19
Next Earnings
Nov 04, 2026EPS Estimate
1.21Next Dividend Ex-DateN/A
Dividend Yield0.19%
Share Statistics
EPS (TTM)3.48
Shares Outstanding454,891,780
10 Day Avg. Volume6,117,812
30 Day Avg. Volume4,946,626
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$77.38Price Target Upside27.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)4.88
Revenue Forecast (FY)$21.79B
Bulls Say, Bears Say
Bulls Say
Record Orders And BacklogSustained order momentum and a large, growing backlog provide durable demand visibility for equipment placements. That supports multi‑period revenue recognition, future service and consumable annuities, and smoother capital allocation, improving medium‑term revenue and cash flow predictability.
Recurring Services & Consumables GrowthServices and consumables growth strengthens recurring revenue mix and typically offers higher gross margins and stable cash conversion. A growing installed base monetized via service contracts and consumables underpins margin resilience and long‑term cash generation even if equipment cycles fluctuate.
PDx Strength And New Product RampHigh‑margin pharmaceutical diagnostics outperformance and early Flyrcado adoption diversify revenue into attractive, recurring, higher‑margin adjacencies. Successful new product commercialization and AI/diagnostic adoption can sustainably lift company margins and expand addressable market over years.
Bears Say
Patient Care Solutions WeaknessA material, loss‑making PCS segment creates persistent drag on consolidated profitability and ties up management attention. The ongoing strategic review signals potential divestiture or restructuring; either path carries execution risk, potential one‑time costs, and uncertain timing for margin recovery.
Free Cash Flow Decline & VolatilityA sharp TTM decline in free cash flow and one‑off refund distortions reduce near‑term financial flexibility for buybacks, investment, or debt paydown. Lower FCF conversion raises reliance on operating improvement to fund medium‑term targets and weakens cushion against cycles or large strategic moves.
Inflation & China HeadwindsSustained component and freight inflation compresses margins unless fully offset by pricing or cost actions. Concurrent China market softness reduces growth in a large market, limiting geographic diversification benefits and prolonging margin recovery, especially in price‑sensitive product lines.
GE Healthcare Technologies Inc News
GEHC FAQ
What was Ge Healthcare Technologies Inc.’s price range in the past 12 months?
Ge Healthcare Technologies Inc. lowest stock price was $58.75 and its highest was $89.77 in the past 12 months.
What is Ge Healthcare Technologies Inc.’s market cap?
Ge Healthcare Technologies Inc.’s market cap is $29.16B.
When is Ge Healthcare Technologies Inc.’s upcoming earnings report date?
Ge Healthcare Technologies Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 96 days.
How were Ge Healthcare Technologies Inc.’s earnings last quarter?
Ge Healthcare Technologies Inc. released its earnings results on Jul 29, 2026. The company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.036 by $0.094.
Is Ge Healthcare Technologies Inc. overvalued?
According to Wall Street analysts Ge Healthcare Technologies Inc.’s price is currently Undervalued.
Does Ge Healthcare Technologies Inc. pay dividends?
Ge Healthcare Technologies Inc. pays a Quarterly dividend of $0.035 which represents an annual dividend yield of 0.19%. See more information on Ge Healthcare Technologies Inc. dividends here
What is Ge Healthcare Technologies Inc.’s EPS estimate?
Ge Healthcare Technologies Inc.’s EPS estimate is 1.21.
How many shares outstanding does Ge Healthcare Technologies Inc. have?
Ge Healthcare Technologies Inc. has 454,891,780 shares outstanding.
What happened to Ge Healthcare Technologies Inc.’s price movement after its last earnings report?
Ge Healthcare Technologies Inc. reported an EPS of $1.13 in its last earnings report, beating expectations of $1.036. Following the earnings report the stock price went up 12.151%.
Which hedge fund is a major shareholder of Ge Healthcare Technologies Inc.?
Currently, no hedge funds are holding shares in GEHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GE Healthcare Technologies Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$77.38 (27.74% Upside)
$77.38 (27.74% Upside)
Blogger Sentiment
Bullish
GEHC Sentiment 86%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 723.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $6.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.90%
12-Months-Change
Fundamentals
Return on Equity
0.19%
Trailing 12-Months
Asset Growth
10.54%
Trailing 12-Months
Company Description
Ge Healthcare Technologies Inc.
GE Healthcare Technologies Inc. (GEHC) is a global medical technology, diagnostics, and digital solutions company that provides equipment, consumables, services, and software used by hospitals, clinics, and research institutions. The company’s core offerings span medical imaging systems, ultrasound, patient monitoring and anesthesia-related devices, and pharmaceuticals/diagnostic agents used in imaging procedures, along with related informatics and workflow tools to help clinicians diagnose, monitor, and treat patients.
GEHC Company Deck
GEHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed strong commercial momentum: record orders, backlog, solid revenue growth, PDx outperformance, AIS margin expansion, and progress on new AI-enabled products and Flyrcado ramp. Offsetting these positives were meaningful near-term challenges in Patient Care Solutions (13.5% organic decline and negative segment EBIT), inflationary headwinds (memory, oil, freight), and cash volatility driven by tariff refunds. Management maintained full-year guidance and reiterated medium-term targets, expressing confidence in recovery actions and the innovation pipeline.View all GEHC earnings summariesGEHC Revenue Breakdown
44.82% Imaging
25.96% AVS
14.96% PCS
14.06% PDx
0.19% Other
GEHC Stock 12 Month Forecast
Average Price Target
$77.38
▲(27.74% Upside)
Technical Analysis
Veeva Systems
―
Healthequity
―
Doximity
―
Tempus AI, Inc. Class A
―
Hinge Health, Inc. Class A
―
Ownership Overview
0.30% Insiders
33.33% Mutual Funds
1.56% Other Institutional Investors
35.71% Public Companies and Individual Investors